Refills on a Schedule II Opioid With a Red-Flag PDMP
A 34-year-old man presents at 6:40 p.m. on a Friday with a paper prescription for oxycodone 10 mg, #60, one tablet every 6 hours as needed, dated 11 days ago. The prescription is written by a Delaware-licensed family physician and contains the notation “2 refills.” The patient says he is leaving for a two-week vacation tomorrow and wants the full 60 tablets plus the refills “to be safe.” The pharmacist reviews Delaware’s prescription monitoring program and sees that 9 days ago the patient received oxycodone 5 mg #28 from a different pharmacy and a prescription for alprazolam 1 mg #60 from a different prescriber 4 days ago. The patient is alert but slurring words slightly and has pinpoint pupils. The physician’s office is closed for the weekend. The pharmacy has no history with this patient.
1. May the pharmacist dispense the oxycodone as written, including the two refills? Explain the legal and professional reasoning.
Read the worked answer
No. The prescription is invalid as written for two independent reasons.
First, oxycodone is a Schedule II controlled substance. Federal law at 21 CFR 1306.12 prohibits refilling a Schedule II prescription, and Delaware’s Controlled Substances Act follows the same rule. A prescriber who wants the patient to receive additional medication must issue a new prescription; the notation “2 refills” does not create authority to refill. The pharmacist may not treat the initial 60 tablets as a fill plus two authorized refills.
Second, even the initial fill is not automatically dispensable. The pharmacist has a corresponding-responsibility duty to resolve red flags before dispensing a controlled substance. The red flags include an early presentation, a recent opioid fill from another pharmacy, a recent benzodiazepine from a different prescriber, slurred speech, and pinpoint pupils. The combination suggests possible central nervous system depression and possible duplicative prescribing. The pharmacist should attempt to contact the prescriber; if the prescriber cannot be reached and the concerns cannot be resolved, the pharmacist must decline to dispense. The pharmacist should document the PMP review, the red flags, the attempted contact, and the reason for refusal. The prescriber’s weekend unavailability does not lower the standard; it simply means the prescription waits.
2. What should the pharmacist do about the suspected impairment and the PDMP findings before making a final decision? Include documentation and reporting considerations.
Read the worked answer
The pharmacist should not release the medication while the patient appears impaired. The immediate priority is safety: keep the patient at the counter or in a private area, avoid confrontation, and consider calling emergency services if the patient is unable to stay safe or is markedly sedated. The pharmacist should not simply hand back the prescription and let the patient drive away without addressing the impairment.
On the legal side, the pharmacist should document the objective findings: slurred speech, pinpoint pupils, the PMP entries, the early fill request, and the prescriber contact attempt. The pharmacist should notify the prescriber when the office reopens. If the pharmacist suspects that the prescription was obtained by fraud, forgery, or misrepresentation, the pharmacist should report the matter to the Delaware Board of Pharmacy and to DEA under the applicable reporting framework; Delaware’s controlled-substance authorities also expect suspicious activity to be documented. A refusal to fill is not a diagnosis, but it must be recorded accurately and factually. The pharmacist should offer naloxone counseling or dispensing if opioid overdose risk is present, consistent with Delaware’s naloxone access rules, and should avoid making accusations that cannot be supported.